FDA Says Vasopressin Wasn’t Pulled for Safety Reasons
Published Date: 7/6/2026
Notice
Summary
The FDA has confirmed that vasopressin in sodium chloride (0.9%, injection) wasn’t taken off the market because of safety or effectiveness problems. This means generic versions can now get approved if they meet all the rules, helping patients and healthcare providers get more options. No changes in price or availability are expected right now, but more generics could be coming soon!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Generic Approvals Allowed for Vasopressin
On July 6, 2026, FDA determined that VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9% injection, 50 units/50 mL (1 unit/mL) was not withdrawn from sale for reasons of safety or effectiveness. That determination allows abbreviated new drug applications (ANDAs) that reference this listed drug to be approved if they meet all other legal and regulatory requirements, which can permit generic versions to enter the market. The product was initially approved July 11, 2024 and Long Grove Pharmaceuticals notified FDA of discontinuation on May 9, 2025.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
2026-13519 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Premarket Approval of Medical Devices
The FDA is asking for public feedback on their paperwork rules for approving the most important and risky medical devices, like life-support machines. This review helps keep devices safe and effective before they hit the market. If you have thoughts, you’ve got until August 5, 2026, to share them—no cost changes, just a check-in on the info they collect.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13346 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Medication Guides for Prescription Drug Products
The FDA is updating how it collects info about Medication Guides—those important leaflets that come with some prescription drugs to keep patients safe. This affects drug makers who must follow new rules about what info to include and how to share it. Comments on these changes are open until July 31, 2026, and the update aims to keep patients informed without adding extra costs.
Previous / Next Documents
Previous: 2026-13490 — Seamless Carbon and Alloy Steel Standard, Line, and Pressure Pipe From the Republic of Korea and the Russian Federation: Final Results of the Expedited First Sunset Review of the Countervailing Duty Orders
The U.S. Department of Commerce decided to keep extra taxes (countervailing duties) on seamless steel pipes from Korea and Russia because removing them could bring back unfair government help to those countries’ pipe makers. This means importers will still pay these duties starting July 6, 2026, protecting U.S. steel producers like Vallourec. So, prices and trade rules stay steady to keep things fair and competitive.
Next: 2026-13493 — Blue Tractor ETF Trust, et al.
Blue Tractor ETF Trust wants to update its investment rules to include more types of financial instruments, giving its funds more ways to grow your money. This change affects investors in their funds and could open up new opportunities starting soon. If anyone wants a hearing about this, they need to ask by July 27, 2026.